Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase (LYMphoNIGHT)

Multicenter, Controlled, Randomized, Open Label, Clinical Study to Assess the Efficacy of Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Management of Upper Limb LYMphedema in Maintenance Phase: LYMphoNIGHT Study

This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess after 3 months of maintenance phase treatment in patients with secondary upper limb lymphedema following breast cancer.

Half of the patient will wear a day-time and night time compression garment (MOBIDERM Autofit) for 3 months during the maintenance phase, while the other half will only wear day-time compression garment.

Study Overview

• Status: Recruiting
• Conditions: Lymphedema of Upper Arm
• Intervention / Treatment: Device: Control group : Day-time compression sleeve; Device: Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit

Detailed Description

The gold standard treatment to achieve volume reduction of lymphedema is based on a Decongestive Lymphedema Therapy (DLT).that consists in 2 consecutive phases: the initial intensive phase which aim is to obtain maximal reduction of lymphedema volume and a second, the maintenance phase which aim is to maintain the initial volumetric reduction achieved during phase 1 as long as possible. The second maintenance phase mostly based on patient self-management of his treatment, is not strictly codified, but includes compression therapy, nutritional recommendations, skin cares, physical exercises and manual lymphatic drainage.

24 hours compression using garments or bandages seems to be crucial for long term management of lymphedema.

Garment and bandages prescriptions for daily treatment are a common practice in the maintenance phase but are often unsuitable for night treatment, as bandages are effective when well applied but are highly dependent on the patients' skills, and garments, due to their nature, can be poorly tolerated leading to low adherence from patients to self-management care. In the end, there is an unmet medical need for night treatment during maintenance phase. .

In this context THUASNE developed a specific night-time garment, for lymphedema maintenance phase. It is a standard Auto-Adjustable Armsleeve using the MOBIDERM® technology.

MOBIDERM® AUTOFIT is a standard self-adjusting compressive MOBIDERM® sleeve, with mitten.

Several small rigid straps are placed throughout the product to facilitate the passage of the arm, to adapt the garment to the morphology of each patient and to tighten it.

A first pilot randomized controlled study demonstrated some benefit to use MOBIDERM Autofit during night-time as an adjuvant treatment to daily compressive garment.

The objective of this new study is to confirm, using a more robust methodology, the effect of Auto-Adjustable MOBIDERM® Autofit Armsleeve on maintenance phase treatment, worn during the night, within the period at risk for the so called rebound effect as reported in several observational studies.

• Study Type: Interventional
• Enrollment (Estimated): 88
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: ISABELLE QUERE, PUPH, MD; Phone Number: +33467337028; Email: i-quere@chu-montpellier.fr
• Study Contact Backup: Name: ASTRID PICOLET; Phone Number: +33640392490; Email: astrid.picolet@thuasne.fr

Study Locations

• France
  • Grenoble, France
    • Recruiting
    • Chu Grenoble
    • Principal Investigator: Sophie BLAISE, MD
  • Montpellier, France
    • Recruiting
    • CHU Montpellier
    • Principal Investigator: Isabelle QUERE, PUPH, MD
  • Mulhouse, France
    • Not yet recruiting
    • Ghr Mulhouse
    • Principal Investigator: Amer HAMADE, MD
  • Nice, France
    • Recruiting
    • CHU Nice
    • Principal Investigator: Pascal GIORDANA, MD
  • Nîmes, France
    • Recruiting
    • Nimes
    • Principal Investigator: Eve VERNHET, MD
  • Toulouse, France
    • Not yet recruiting
    • CHU Toulouse
    • Principal Investigator: Julie MALLOIZEL, MD
  • Tours, France, 37044
    • Not yet recruiting
    • CHRU Tours
    • Sub-Investigator: Loic VAILLANT, PUPH,MD
    • Principal Investigator: Valerie TAUVERON, MD
• Turkey
  • Ankara, Turkey
    • Recruiting
    • Turkey
    • Principal Investigator: Pinar BORMAN, MD
    • Sub-Investigator: Burcu CAKIT, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Women responding positively to the lymphedema reduction phase defined by a ≥ 30% decrease in lymphedema volume at the end of DLT
• Unilateral secondary upper limb lymphedema of stage II or III according to the criteria defined by the International Society of Lymphology, following breast cancer
• Affected arm that fits with one of the 6 standard sizes of the Auto-Adjustable MOBIDERM® Autofit armsleeve provided
• Signed informed consent prior to any study-mandated procedure
• Affiliated to the General regime of the Social Security or covered by a similar health insurance system

Non-inclusion criteria :

• Stage I lymphedema or located in several places
• Active cellulitis / Infectious dermo-hypodermatitis
• Lymphedema associated with active cancer needing acute chemotherapy
• Motor and sensitive neurological deficiency / psychiatric or addictive disorders
• Post-operative edema (i.e acute edema occurring during the days following breast cancer-related surgery)
• Patients for whom compression is contraindicated, such as untreated infections, skin irritation, thrombosis, presence of skin lesions on the armsleeve placement
• Pregnant or breastfeeding patient
• Previous history of hypersensitivity to MOBIDERM® technology or lymphatrex garment General conditions
• Participation to any other clinical study which has an impact on the different endpoints
• Unlikely to be followed up to 3 months with clinical assessment as per investigator's judgment
• Vulnerable patient according to the article L.1121-6 of the French Public Health Code, the adults being the object of a legal protective measure or enable to express their consent according to the article L.1121-8 of French Public Health Code

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control group : Day-time compression sleeve; Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.	Device: Control group : Day-time compression sleeve; In the control group, patients wear only day-time compression garment : lymphatrex during 3 months. The protocol will require 3 visits during the maintenance phase. Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group). Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group) Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).
Experimental: Day-time compression sleeve and Night-time MOBIDERM Autofit; Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.	Device: Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit; In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months. The protocol will require 3 visits during the maintenance phase. Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group). Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group) Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The volume excess variation	The primary endpoint of this study is to compare the volume excess variation of the upper limb between both groups from D0 to D90. Volume excess is defined as the volumetric difference between the affected upper limb compared to the contralateral upper limb, calculated with truncated cone formula.	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The quality of life (QoL): LYMQOL ARM self-questionnaire	The evolution of QoL is measured by LYMQOL ARM self-questionnaire and specific questions. This tool was designed as patient-completed questionnaire. The questions cover four domains : symptoms, body image/appearance, function, mood. Each item in each domain was scored : not at all (1), a little (2), Quite a bit (3), A lot (4). Specific questions are about patient's perception of benefit.	30 and 90 days
The range of motion	The evolution of range of motion of the arm is measured by joint movements : Antepulsion (flexion), retropulsion (extension), total abduction, adduction, lateral rotation (external rotation), medial rotation (internal rotation)	30 and 90 days
The volume excess variation	Volume excess is defined as the volumetric difference between the affected upper limb compared to the contralateral upper limb, calculated with truncated cone formula.	30 days
Patient's opinion on Global Impression of Change (PGI-C)	Patient's opinion on Global Impression of Change about her general condition is measured by the modified PGI-C questionnaire (Patient's opinion on Global Impression of Change). The scale has 7 levels from "no change or condition has got worsed"(worse outcome) to "a great deal better, and a considerable improvement that has made all the difference ( better outcome)". Intermediate levels are: "almost the same, hardly any change at all"; "a little better, but no noticeable change", "somewhat better, but the change has not made any real difference"; "moderately better, and a slight but noticeable change"; "better, and a definite improvement that has made a real and worthwhile difference.	30 and 90 days
Doctors' opinion on improving the patient's health condition (Clinical Global Improvement Impression)	Doctors' opinion on improving the patient's health condition caused by lymphedema is measured by the CGI-I modified questionnaire (Clinical Global Improvement Impression). This questionnaire allows doctors to evaluate the improvement of patients. The scale has 7 levels from "very strongly improved"(better outcome) to "very strongly aggravated"(worse outcome).Intermediate levels are: " Significantly improved " ; " Slightly improved " ; " No improvement " ; " Slightly aggravated " ; " Seriously aggravated ".	30 and 90 days
Doctors' opinion on severity about the lymphedema (CGI-S)	Doctors' opinion on severity about the lymphedema is measured by CGI-S. This questionnaire assesses the severity of lymphedema. This scale has 7 levels from "normal, not sick at all" (better outcome) to " among the most severely ill patients "(worse outcome). Intermediate levels are: " borderline ill " ; " slightly ill " ; " moderately ill " ; " clearly ill " ; " severely ill ".	30 and 90 days
number of days/nights : The compliance to treatment	The compliance to treatment (day-time and night-time only for Intervention Group) is reported by the physician in the e-CRF according to the patient diary. The compliance is measured in number of days and or nights (groupe I) when the device was worn and the average wearing time was : Full day/night, >50% of the day/night,<50% of the day/night	30 and 90 days
The evolution of quality of sleep: Jenkins self-questionnaire	The evolution of quality of sleep is measured by Jenkins self-questionnaire. This scale is composed of four questions about the quality of sleep.	30 and 90 days
The satisfaction about the device: questionnaire	Patient's satisfaction with regards to MOBIDERM® Autofit for patients from intervention group only by a satisfaction questionnaire. This questionnaire is focused on the product positioning and the comfort.	90 days
Number and type of serious and non-serious Adverse Device Effects	Number and type of serious and non-serious Adverse Device Effects (ADE) with a focus on cutaneous ADE will be reported during the study.	90 days
The elastometry	To compare the evolution of skin thickness, elasticity, suppleness on a subgroup of patients by ultrasound.	30 and 90 days
The percentage of patients presenting with a failure of maintenance	Percentage of patients presenting with a failure of maintenance phase, defined by a volume increase ≥ 30% of the volume reduction observed during intensive phase of decongestive lymphedema therapy (DLT)	30 and 90 days
The satisfaction about the daytime device: questionnaire	Patient's satisfaction with regards to daytime device for all patients by a satisfaction questionnaire. This questionnaire is focused on the product positioning and the comfort.	90 days
The quality of life (QoL): EQ-5D-5L self-questionnaire	The evolution of QoL is measured by EQ5D 5L self-questionnaire. This tool was designed as patient-completed questionnaire. The questions cover five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.	30 and 90 days

Collaborators and Investigators

• Sponsor: Thuasne
• Collaborators: International Clinical Trials Association
• Investigators: Principal Investigator: ISABELLE QUERE, PUPH,MD, University Hospital, Montpellier

Publications and helpful links

General Publications

• Quere I, Presles E, Coupe M, Vignes S, Vaillant L, Eveno D, Laporte S, Leizorovicz A; POLIT Study investigators. Prospective multicentre observational study of lymphedema therapy: POLIT study. J Mal Vasc. 2014 Jul;39(4):256-63. doi: 10.1016/j.jmv.2014.05.004. Epub 2014 Jun 12.
• Mestre S, Calais C, Gaillard G, Nou M, Pasqualini M, Ben Amor C, Quere I. Interest of an auto-adjustable nighttime compression sleeve (MOBIDERM(R) Autofit) in maintenance phase of upper limb lymphedema: the MARILYN pilot RCT. Support Care Cancer. 2017 Aug;25(8):2455-2462. doi: 10.1007/s00520-017-3652-5. Epub 2017 Mar 9.
• Brown JC, Cheville AL, Tchou JC, Harris SR, Schmitz KH. Prescription and adherence to lymphedema self-care modalities among women with breast cancer-related lymphedema. Support Care Cancer. 2014 Jan;22(1):135-43. doi: 10.1007/s00520-013-1962-9. Epub 2013 Sep 7.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2020
• Primary Completion (Actual): December 30, 2023
• Study Completion (Estimated): February 15, 2024

Study Registration Dates

• First Submitted: December 16, 2019
• First Submitted That Met QC Criteria: December 17, 2019
• First Posted (Actual): December 18, 2019

Study Record Updates

• Last Update Posted (Actual): February 2, 2024
• Last Update Submitted That Met QC Criteria: February 1, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Lymphedema of upper arm; Auto-Adjustable MOBIDERM® Autofit Armsleeve; Compression garments; Maintenance phase
• Additional Relevant MeSH Terms: Lymphatic Diseases; Lymphedema
• Other Study ID Numbers: EC29; ANSM (Other Identifier: 2022-A02513-40)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No